Sign-up for Kamada Announces Positive Interim Results from Phase I/II Clinical Study of its Human Alpha-1 Antitrypsin to Treat Graft-versus-Host Disease Presented at the American Society of Hematology Annual Meeting investment picks
plc (NASDAQ: ALKS) today announced the initiation of a phase 1
clinical study of extended dosing intervals of aripiprazole lauroxil,
the company’s investigational, novel, long-acting injectable atypical
antipsychotic for the treatment of schizophrenia.
PALATINE, IL--(Marketwired - February 16, 2015) - Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), today announced the initiation of treatment in a pilot clinical study of two experimental formulations of NEXAFED (pseudoephedrine HCl) extended-release tablets employing Acura's 2 nd generation methamphetamine resistant technology, IMPEDE 2.0. The study in fasted, healthy subjects will measure the systemic absorption of the active ingredient, pseudoephedrine, from two experimental NEXAFED extended-release formulations compared to an FDA-approved 12-hour extended-release reference product.
NEWARK, CA--(Marketwired - January 12, 2015) - CymaBay Therapeutics Inc. (NASDAQ: CBAY) today announced positive preliminary results from its clinical study of arhalofenate administered in combination with febuxostat (Uloric™, Takeda Pharmaceutical Company Limited). Arhalofenate is a once-daily, oral candidate for the treatment of gout with a unique dual mechanism of action which lowers serum uric acid (sUA) while also reducing the occurrence of gout flares.
Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today that dosing has
begun in a Phase IIa clinical study evaluating whether its
investigational guanylate cyclase-C (GC-C) agonist, IW-9179, can provide
symptomatic relief to patients with diabetic gastroparesis.
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company,
today announced the first patient enrollment in the STAR-VT ( S ubstrate
T argeted A blation using the FlexAbility™ Ablation Catheter
System for the R eduction of V entricular T achycardia)
clinical trial, a prospective, multi-center, randomized study evaluating
the safety and efficacy of the FlexAbility™ ablation catheter when used
in ventricular tachycardia (VT) ablation procedures.
NEWARK, CA--(Marketwired - February 24, 2015) - CymaBay Therapeutics, Inc. (NASDAQ: CBAY) today announced positive preliminary topline results from its Phase 2b clinical study of its lead product candidate, arhalofenate, for the treatment of gout.
Aurinia Pharmaceuticals Inc. (the “Company”) (NASDAQ:AUPH) (TSX:AUP)
today announced that it will initiate an open label, exploratory study
to assess the short term predictors of response using voclosporin in
combination with mycophenolate mofetil in patients with active lupus
Sign-up for Clinical Study Results Presented at the 2015 Gastrointestinal Cancer Symposium Support Utility of Trovagene's Precision Cancer Monitoring Platform in Colorectal and Pancreatic Cancer Patients investment picks
Heron Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company, today
announced the initiation of a Phase 1 clinical trial of HTX-011, which
is being developed for the treatment of post-operative pain.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.